MedTrace Logo

High Flow Nasal Cannula in Immediately Post Extubation

NCT03495947 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 165

Last updated 2019-03-04

No results posted yet for this study

Summary

The aim of the study is to determine the incidence of failure of extubation in high-risk patients using High Flow Nasal Cannula (HFNC) to prevent such failure in the Intensive Care Unit. A prospective cohort study was performed. To all adult patients receiving invasive mechanical ventilation ≥ 48 hours and ready for scheduled extubation according to tolerance of spontaneous breathing trial, with at least one of the criteria for high-risk for extubation failure (age greater than 65 years, hypoxemic acute respiratory failure as a cause of invasive mechanical ventilation, \> 1 spontaneous ventilation test failed consecutive, history of chronic heart failure, history of chronic obstructive pulmonary disease or PaCO2\> 45 mmHg, body mass index \>30 kg/m2, post-operative solid organ transplantation), HFNC is applied for 24 hours. Demographic variables and clinical and gasometric parameters at the end of the spontaneous breathing trial, at 60 minutes, at 6 and 24 hours after the start of HFNC are recorded.

Conditions

  • Airway Extubation
  • Oxygen Inhalation Therapy

Interventions

BEHAVIORAL

high flow nasal cannula

24 hours of continuous use in the immediate post-extubation period.

Sponsors & Collaborators

  • Hospital Italiano de Buenos Aires

    lead OTHER

Principal Investigators

  • Paulina E Ezcurra, Lic

  • Maria S Venuti, Dr

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-01
Primary Completion
2019-01-03
Completion
2019-01-03

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03495947 on ClinicalTrials.gov